P
CYTK icon

Pitcairn’s Cytokinetics CYTK Stock Holding History

Pitcairn’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,853
Closed -$228K – 714
2024
Q4 		$228K Sell
4,853
-38
-0.8% -$1.97K 0.01% 653
2024
Q3 		$258K Sell
4,891
-755
-13% -$42.1K 0.02% 631
2024
Q2 		$306K Buy
5,646
+521
+10% +$31.4K 0.02% 582
2024
Q1 		$359K Hold
5,125
– – 0.02% 526
2023
Q4 		$428K Buy
+5,125
New +$186K 0.03% 445
2023
Q1 		– Sell
-5,424
Closed -$249K – 605
2022
Q4 		$249K Sell
5,424
-218
-4% -$9.38K 0.02% 512
2022
Q3 		$273K Buy
5,642
+181
+3% +$8.71K 0.03% 460
2022
Q2 		$215K Buy
+5,461
New +$220K 0.02% 541

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pitcairn's CYTK Position: Q1 2025 in Review

Pitcairn sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 4,853 shares — an estimated $228K sold.

Pitcairn first reported a position in CYTK in Q2 2022 and held it in 8 quarters. The position peaked at $428K in Q4 2023. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Pitcairn reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Pitcairn sold 4,853 Cytokinetics shares in Q1 2025, an estimated $228K.
  • Pitcairn first reported a position in Cytokinetics in Q2 2022 and held it in 8 quarters.
  • Pitcairn's Cytokinetics position peaked at $428K in Q4 2023.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Pitcairn's 13F filing for Q1 2025, filed 9 May 2025.